Text Size

Early Palliative Care With Standard Oncology Care Versus Standard Oncology Care Alone in Advanced Lung and Non-colorectal Gastrointestinal Malignancies

This study is currently recruiting participants.
Verified April 2013 by Massachusetts General Hospital
Sponsor:
Information provided by (Responsible Party):
Jennifer Temel, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01401907
First received: July 20, 2011
Last updated: April 23, 2013
Last verified: April 2013
History of Changes
  Purpose

The purpose of this study is to compare two types of care - standard oncology care and standard oncology care with early palliative care (started soon after diagnosis) to see which is better for improving the experience of patients and families with advanced lung and non-colorectal GI cancer. The study will use questionnaires to measure patients' and caregivers' quality of life, mood, coping and understanding of their illness.


Condition Intervention Phase
Non-small Cell Lung Cancer
Small Cell Lung Cancer
Mesothelioma
Esophageal Cancer
Gastric Cancer
Liver Cancer
Pancreatic Cancer
 Other: early palliative care
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Advanced Lung and Non-colorectal Gastrointestinal Malignancies

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Functional Assessment of Cancer Therapy (Quality of life measure) [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Functional Assessment of Cancer Therapy (Quality of life measure) [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Hospital Anxiety and Depression Scale (Mood) [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Hospital Anxiety and Depression Scale (Mood) [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Prognostic Understanding [ Time Frame: 12 and 24 weeks ] [ Designated as safety issue: No ]
  • Family Caregiver Quality of Life (SF-36) [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Family Caregiver Hospital Anxiety and Depression Scale (Mood) [ Time Frame: baseline and 12 weeks ] [ Designated as safety issue: No ]
  • Family Caregiver Prognostic Understanding [ Time Frame: 12 and 24 weeks ] [ Designated as safety issue: No ]
  • Resource utilization at the end of life (EOL) [ Time Frame: after death ] [ Designated as safety issue: No ]
    chemotherapy utilization at the EOL hospice utilization (referral rate and length of stay)

  • Health Care Costs [ Time Frame: after death ] [ Designated as safety issue: No ]
  • Code Status Documentation [ Time Frame: after death ] [ Designated as safety issue: No ]
  • Coping (Brief Cope) [ Time Frame: baseline to 12 weeks ] [ Designated as safety issue: No ]
  • Coping (Brief Cope) [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
  • Family Caregiver Quality of Life (SF-36) [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • Additional resource utilization [ Time Frame: after death ] [ Designated as safety issue: No ]
    hospital admissions emergency room admissions intensive care unit admissions resuscitation attempt

  • Survival [ Time Frame: time to death ] [ Designated as safety issue: No ]

Estimated Enrollment: 350
Study Start Date: May 2011
Estimated Study Completion Date: April 2016
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Early Palliative Care
Subjects receive standard of care with early palliative care.
 Other: early palliative care
patient assigned to the intervention will receive early palliative care along with standard oncology care.
No Intervention: Standard of Care
Subjects receives standard of care

Detailed Description:

Subjects and their caregiver will complete a baseline questionnaire and then be randomized to a study group.

Subjects who are randomized to Standard Oncology Care will follow up with their treating oncologist. They will consult with the palliative care team at their request or at the request of the treating oncologist. They will complete questionnaires at 12 weeks and 24 weeks after enrollment.

Subjects who are randomized to the Standard Oncology Care with Early Palliative Care will meet with a palliative care clinician at their next medical oncology visit or infusion visit. They will meet with the palliative care clinician at least every three weeks. They will complete questionnaires at 12 and 24 weeks after enrollment.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmed metastatic lung cancer (NSCLC, small cell lung cancer, and mesothelioma)or non-colorectal GI cancer (esophageal, gastric and hepatobiliary) not being treated with curative intent
  • Informed of metastatic disease within the previous 8 weeks
  • No prior therapy for metastatic disease
  • Able to read questions in English or willing to complete questionnaires with the assistance of an interpreter
  • Relative or friend of patient who will likely accompany the patient to clinic visits

Exclusion Criteria:

  • Significant psychiatric or other co-morbid disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01401907

Contacts
Contact: Jennifer Temel, MD 617-726-8743 jtemel@partners.org

Locations
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Principal Investigator: Jennifer Temel, MD            
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
Principal Investigator: Jennifer Temel, MD Massachusetts General Hospital
  More Information

No publications provided

Responsible Party: Jennifer Temel, MD, Principal Investigator, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01401907     History of Changes
Other Study ID Numbers: 10-434
Study First Received: July 20, 2011
Last Updated: April 23, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
Palliative care
Lung
Gastric
Liver
 Pancreatic
Esophageal
Caregiver

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Esophageal Diseases
Esophageal Neoplasms
Liver Neoplasms
Lung Neoplasms
Stomach Neoplasms
Mesothelioma
Pancreatic Neoplasms
Small Cell Lung Carcinoma
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
 Lung Diseases
Respiratory Tract Diseases
Gastrointestinal Diseases
Digestive System Diseases
Gastrointestinal Neoplasms
Digestive System Neoplasms
Head and Neck Neoplasms
Liver Diseases
Stomach Diseases
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Mesothelial
Endocrine Gland Neoplasms
Pancreatic Diseases

ClinicalTrials.gov processed this record on May 19, 2013